Catalyst Pharma patent trial delayed to May 18, 2026 in NJ district court

CATALYST PHARMACEUTICALS, INC.

District Court of NJ delayed bench trial between Catalyst and Hetero USA from Mar 23 to May 18, 2026.
Trial concerns validity of Orange Book-listed patents for FIRDAPSE expiring in 2032, 2034, and 2037.
The trial is a bench trial (judge only) and will be held in the District of New Jersey.

item 8.01

CATALYST PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-26-114764

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.